Aims-To determine whether there is a correlation between activation of the ras oncogene and the induction of MHC class II antigens and intercellular adhesion molecule 1 (ICAM-1) by interferon-y (IFN-y).
Inflammatory responses in tissues are often accompanied by augmentation of the expression of class II MHC antigens (HIA DR, DP and DQ) and of intercellular adhesion molecule 1 (ICAM-1) by cells. This is particularly apparent in rejection of allografts (for example, kidney') and in autoimmune disease (for example, inflammatory bowel disease2) and is ascribed to the production of cytokines, especially interferon-y (IFN-y), by activated T cells.
Inflammatory responses occur in a proportion of patients with cancer, with infiltration by leucocytes and upregulation at least of HLA DR. T cells responding in an MHC restricted manner to self antigens expressed by the tumours have been identified, suggesting that in some instances these inflammatory responses may be specific immune responses (reviewed in 3). There are some reports that a strong inflammatory response is indicative of a better prognosis (for example, in carcinoma of the larynx,4 breast,5 stomach,6 and colorectum7) and experimental data showing that expression of class II histocompatibility antigens by tumour cells influences their tumorigenicity.8 9 However, the extent of the inflammatory response in cancer is highly variable, with the degree of leucocytic infiltration ranging from virtually nil to very extensive, and the expression of class II antigens and ICAM-1 equally ranging from nil to very intense, with little correlation between the two. This variation may be related to differing capacities of tumour cells to respond to cytokines by upregulation of class II antigens and ICAM-1.
We have demonstrated recently that tumour cells from most colorectal carcinomas which are negative for expression of MHC class II antigens and ICAM-1 are incapable of responding to IFN-y by upregulating these molecules.'0 In this paper we seek to demonstrate that this failure of response may be related to the activation of the proto-oncogene Ki-ras in the tumour cells, arguing that the subversion of intracellular signalling pathways resulting from such activation may disrupt cytokine responses.
The importance of the family of ras oncogenes is that it plays a central role in intracellular pathways, transducing growth factor signals from the cell membrane to the nucleus.
The products of the ras oncogenes are small GTPases of 21 kDa (p21ras) whose function is to transmit the signal from activated growth factor receptors to the raf gene product and thence via a series of mitogen activated kinases (MAP kinases) to the nucleus, where transcription of a range of genes important in cellular proliferation is stimulated."' Activation of ras by mutation or overexpression, or by subversion of other components of the pathway involving the ras gene product, results in stimulation of cell proliferation. In a number of human cancers there is activation of ras and in The following established colorectal cell lines:
Caco-2, Colo201, Colo205, HCT116, HT29, LoVo, LS180, SW1417, and SW1417, were supplied by the American Type Culture Collection (ATCC Rockville, Maryland, USA) or the European Collection of Animal Cell Culture (ECACC: Public Health Laboratory Service, Porton Down, UK). Cell culture medium used was RPMI (Gibco BRL) supplemented with "Myoclone Plus" fetal calf serum (Gibco BRL). All incubation and culture procedures were carried out at 37°C in 5% CO2.
To prepare tumour cell suspensions, the excised tumours were dissected to remove obvious necrotic tissue and blood clots, and were then washed in cold RPMI medium to remove surface contamination. The tumours were then minced, followed by enzymatic disaggregation with 0-01 mg/ml hyaluronidase type V (Sigma, Poole, Dorset, UK), 0-02 mg/ml DNase type I (Boehringer Mannheim, Mannheim, Germany), 1 mg/ml collagenase A (Boehringer Mannheim) in RPMI medium containing 10% "Myoclone Plus" serum by gentle shaking at room temperature for about 15 
Results

EXPRESSION OF CLASS II ANTIGENS AND ICAM-1 BY TUMOUR CELL LINES
It was apparent that there was great variation in the expression of both class II antigens and ICAM-1 after treatment with IFN-y and that the lines also showed heterogeneity of ICAM-1 expression in the absence of IFN-y treatment. However, as all of the lines were essentially negative for class II antigen expression in the absence of IFN-y treatment, it was possible to arrange the lines in order of inducibility for class II antigens: four lines (HT29, Colo2O5, SW1417, and Colo201) were all strongly inducible (fluoresence intensity more than 10-fold greater than without IFN-y); LoVo was weakly inducible (less than twofold); two (Caco-2 and LS 180) did not show significant inducibility, whilst two other lines (HCT1 16 and SW1463) showed heterogeneity of expression after treatment with IFN-y. Because of the constitutive expression of ICAM-1 by some of the lines, it is impossible to give an unequivocal order for its inducibility. However, there did seem to be a rough correlation between expression of the two, as the four lines which showed the most class II antigen induction were also relatively strongly inducible for ICAM-1, while three weakly inducible for class II antigens were also weakly inducible for ICAM-1. Of the two lines heterogeneous for induction of class II antigen expression, one showed strong ICAM-1 induction and the other was heterogeneous.
These data for class II antigen and ICAM-1 expression are summarised in table 2. will be a one to one relation between ras activation and failure of class II antigen/ICAM-1 induction.
Inducibility of cells from the tumour ID11 containing the GGT-+TGT mutation, replacing Gly with Cys, is not so easily explained. However, there is evidence that not all mutations in ras affect its functioning equally. In an extensive series of experiments Seeburg et al30 showed that the transforming ability of different codon 12 mutations varied with the amino acid substitution. It is also clear that codon 13 mutations affect the GTPase activity of p2lras less than do codon 12 mutations.31 More recently, work by Finkelstein et al32 with colorectal carcinoma has suggested that the nature of the mutations of the ras gene could influence the biological behaviour ofthe cancer. In this instance the finding was that the particular substitution correlated with the degree of cancer spread. In particular, tumours with a Gly-÷Val substitution were indolent whilst those with a Gly-+Asp mutation were very aggressive. Similar results have been obtained in pancreatic carcinoma.33 It is therefore possible that the mutation occurring in ID 1 1 (Gly--Val substitution at codon 12) which was IFN inducible was such that the IFN signalling pathway was less affected.
In summary, these data indicate that whilst ras activation may play a role in controlling responses to cytokines, clearly there are other important factors involved. 
